Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Israel, Iran show restraint. But for how long?Owen Miller's twoOlivia Rodrigo shows off her abs in a bikini during sunny getawayI auditioned for Britain's Got Talent ten years ago and it looks nothing like what you see on TVChinese foreign minister arrives in Cambodia, Beijing's closest Southeast Asian allyOne Extraordinary Photo: Covering the MastersPaul Mescal is a splash hit... and that's before the heartMan United back in another FA Cup final against Man City after narrowly avoiding humiliationRosanna Arquette gushes over Pulp Fiction coMP Mark Menzies, who allegedly misused campaign funds, won't seek reelection
1.7861s , 5764.78125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Compass news portal